BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cui J, Wang N, Zhao H, Jin H, Wang G, Niu C, Terunuma H, He H, Li W. Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression-free survival for patients with hepatocellular carcinoma. Int J Cancer. 2014;134:342-351. [PMID: 23825037 DOI: 10.1002/ijc.28372] [Cited by in Crossref: 57] [Cited by in F6Publishing: 57] [Article Influence: 6.3] [Reference Citation Analysis]
Number Citing Articles
1 Greten TF, Wang XW, Korangy F. Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches. Gut 2015;64:842-8. [PMID: 25666193 DOI: 10.1136/gutjnl-2014-307990] [Cited by in Crossref: 110] [Cited by in F6Publishing: 113] [Article Influence: 15.7] [Reference Citation Analysis]
2 Wang Y, Wang C, Xiao H, Niu C, Wu H, Jin H, Yao C, He H, Tian H, Han F, Li D, Han W, Xu J, Chen J, Cui J, Li W. Adjuvant treatment combining cellular immunotherapy with chemotherapy improves the clinical outcome of patients with stage II/III gastric cancer. Cancer Med 2017;6:45-53. [PMID: 27790867 DOI: 10.1002/cam4.942] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
3 Shen S, Peng H, Wang Y, Xu M, Lin M, Xie X, Peng B, Kuang M. Screening for immune-potentiating antigens from hepatocellular carcinoma patients after radiofrequency ablation by serum proteomic analysis. BMC Cancer 2018;18:117. [PMID: 29386009 DOI: 10.1186/s12885-018-4011-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
4 Kabilova TO, Kovtonyuk LV, Zonov EV, Ryabchikova EI, Popova NA, Nikolin VP, Kaledin VI, Zenkova MA, Vlassov VV, Chernolovskaya EL. Immunotherapy of hepatocellular carcinoma with small double-stranded RNA. BMC Cancer 2014;14:338. [PMID: 24886485 DOI: 10.1186/1471-2407-14-338] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
5 Wu MY, Yiang GT, Cheng PW, Chu PY, Li CJ. Molecular Targets in Hepatocarcinogenesis and Implications for Therapy. J Clin Med. 2018;7. [PMID: 30104473 DOI: 10.3390/jcm7080213] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
6 Liu B, He X, Wang Y, Huang J, Zheng Y, Li Y, Lu L. Bibliometric Analysis of γδ T Cells as Immune Regulators in Cancer Prognosis. Front Immunol 2022;13:874640. [DOI: 10.3389/fimmu.2022.874640] [Reference Citation Analysis]
7 Lee JH, Tak WY, Lee Y, Heo MK, Song JS, Kim HY, Park SY, Bae SH, Lee JH, Heo J, Kim KH, Bae YS, Kim YJ. Adjuvant immunotherapy with autologous dendritic cells for hepatocellular carcinoma, randomized phase II study. Oncoimmunology 2017;6:e1328335. [PMID: 28811965 DOI: 10.1080/2162402X.2017.1328335] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
8 Singh P, Toom S, Avula A, Kumar V, Rahma OE. The Immune Modulation Effect of Locoregional Therapies and Its Potential Synergy with Immunotherapy in Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2020;7:11-17. [PMID: 32104669 DOI: 10.2147/jhc.s187121] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
9 Gardiner RE, Jahangeer S, Forde P, Ariffin AB, Bird B, Soden D, Hinchion J. Low immunogenicity in non-small cell lung cancer; do new developments and novel treatments have a role? Cancer Metastasis Rev 2015;34:129-44. [PMID: 25726003 DOI: 10.1007/s10555-015-9550-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
10 Bo XW, Sun LP, Yu SY, Xu HX. Thermal ablation and immunotherapy for hepatocellular carcinoma: Recent advances and future directions. World J Gastrointest Oncol 2021; 13(10): 1397-1411 [PMID: 34721773 DOI: 10.4251/wjgo.v13.i10.1397] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
11 Chen L, Sun J, Yang X. Radiofrequency ablation-combined multimodel therapies for hepatocellular carcinoma: Current status. Cancer Lett. 2016;370:78-84. [PMID: 26472630 DOI: 10.1016/j.canlet.2015.09.020] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 4.4] [Reference Citation Analysis]
12 Guo H, Li L, Cui J. Advances and challenges in immunotherapy of small cell lung cancer. Chin J Cancer Res 2020;32:115-28. [PMID: 32194311 DOI: 10.21147/j.issn.1000-9604.2020.01.13] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
13 Bhat J, Placek K, Faissner S. Contemplating Dichotomous Nature of Gamma Delta T Cells for Immunotherapy. Front Immunol 2022;13:894580. [DOI: 10.3389/fimmu.2022.894580] [Reference Citation Analysis]
14 Nakamoto Y. Promising new strategies for hepatocellular carcinoma. Hepatol Res. 2017;47:251-265. [PMID: 27558453 DOI: 10.1111/hepr.12795] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
15 Wang K, Wang C, Jiang H, Zhang Y, Lin W, Mo J, Jin C. Combination of Ablation and Immunotherapy for Hepatocellular Carcinoma: Where We Are and Where to Go. Front Immunol 2021;12:792781. [PMID: 34975896 DOI: 10.3389/fimmu.2021.792781] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Zeng Z, Yang B, Liao ZY. Current progress and prospect of immune checkpoint inhibitors in hepatocellular carcinoma. Oncol Lett 2020;20:45. [PMID: 32802167 DOI: 10.3892/ol.2020.11909] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
17 Gans JH, Lipman J, Golowa Y, Kinkhabwala M, Kaubisch A. Hepatic Cancers Overview: Surgical and Chemotherapeutic Options, How Do Y-90 Microspheres Fit in? Seminars in Nuclear Medicine 2019;49:170-81. [DOI: 10.1053/j.semnuclmed.2019.01.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
18 Yu M, Luo H, Fan M, Wu X, Shi B, Di S, Liu Y, Pan Z, Jiang H, Li Z. Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma. Mol Ther. 2018;26:366-378. [PMID: 29339014 DOI: 10.1016/j.ymthe.2017.12.012] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 11.4] [Reference Citation Analysis]
19 Xie H, Yu H, Tian S, Yang X, Wang X, Wang H, Guo Z. MEIS-1 level in unresectable hepatocellular carcinoma can predict the post-treatment outcomes of radiofrequency ablation. Oncotarget 2018;9:15252-65. [PMID: 29632641 DOI: 10.18632/oncotarget.24165] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
20 Yang W. Current status and prospective of imaging guided radiofrequency ablation in medium to large sized hepatocellular carcinomas. Shijie Huaren Xiaohua Zazhi 2015; 23(30): 4771-4777 [DOI: 10.11569/wcjd.v23.i30.4771] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
21 Cao J, Kong FH, Liu X, Wang XB. Immunotherapy with dendritic cells and cytokine-induced killer cells for hepatocellular carcinoma: A meta-analysis. World J Gastroenterol 2019; 25(27): 3649-3663 [PMID: 31367163 DOI: 10.3748/wjg.v25.i27.3649] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 22] [Article Influence: 7.7] [Reference Citation Analysis]
22 Ding X, Cao H, Chen X, Zhao Y, Jin H, Niu C, Ma K, Liu Z, Chen J, Wang X, Yang L, He H, Han W, Li D, Tian H, Li W, Cui J. Cellular immunotherapy as maintenance therapy prolongs the survival of the patients with small cell lung cancer in extensive stage. Journal of Cellular Immunotherapy 2016;2:36-43. [DOI: 10.1016/j.jocit.2016.02.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
23 Qian L, Wang N, Tian H, Jin H, Zhao H, Niu C, He H, Ge T, Han W, Hu J, Li D, Han F, Xu J, Ding X, Chen J, Li W, Cui J. Dual Effects of Cellular Immunotherapy in Inhibition of Virus Replication and Prolongation of Survival in HCV-Positive Hepatocellular Carcinoma Patients. J Immunol Res. 2016;2016:6837241. [PMID: 27069936 DOI: 10.1155/2016/6837241] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
24 Biondetti P, Saggiante L, Ierardi AM, Iavarone M, Sangiovanni A, Pesapane F, Fumarola EM, Lampertico P, Carrafiello G. Interventional Radiology Image-Guided Locoregional Therapies (LRTs) and Immunotherapy for the Treatment of HCC. Cancers (Basel) 2021;13:5797. [PMID: 34830949 DOI: 10.3390/cancers13225797] [Reference Citation Analysis]
25 Tian M, Shi Y, Liu W, Fan J. Immunotherapy of hepatocellular carcinoma: strategies for combinatorial intervention. Sci China Life Sci 2019;62:1138-43. [PMID: 31119560 DOI: 10.1007/s11427-018-9446-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
26 Zhang Z, Wang L, Luo Z, Zhao X, Huang J, Li H, Yang S, Zhao X, Zhang L, Li L, Wang F, Huang L, Zhang Y. Efficacy and safety of cord blood–derived cytokine-induced killer cells in treatment of patients with malignancies. Cytotherapy 2015;17:1130-8. [DOI: 10.1016/j.jcyt.2015.04.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
27 Chen JL, Lao XM, Lin XJ, Xu L, Cui BK, Wang J, Lin GH, Shuang ZY, Mao YZ, Huang X, Yun JP, Jin JT, Li SP. Adjuvant Cytokine-Induced Killer Cell Therapy Improves Disease-Free and Overall Survival in Solitary and Nonmicrovascular Invasive Hepatocellular Carcinoma After Curative Resection. Medicine (Baltimore) 2016;95:e2665. [PMID: 26844496 DOI: 10.1097/MD.0000000000002665] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
28 Zhao K, Yang W. Effect of ablation of solid tumors on immune function: Clinical application of combined immunotherapy. Shijie Huaren Xiaohua Zazhi 2018; 26(23): 1385-1389 [DOI: 10.11569/wcjd.v26.i23.1385] [Reference Citation Analysis]
29 Craciun L, de Wind R, Demetter P, Lucidi V, Bohlok A, Michiels S, Bouazza F, Vouche M, Tancredi I, Verset G, Garaud S, Naveaux C, Galdon MG, Gallo KW, Hendlisz A, Derijckere ID, Flamen P, Larsimont D, Donckier V. Retrospective analysis of the immunogenic effects of intra-arterial locoregional therapies in hepatocellular carcinoma: a rationale for combining selective internal radiation therapy (SIRT) and immunotherapy. BMC Cancer 2020;20:135. [PMID: 32075608 DOI: 10.1186/s12885-020-6613-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
30 Wu K, Feng J, Xiu Y, Li Z, Lin Z, Zhao H, Zeng H, Xia W, Yu L, Xu B. Vδ2 T cell subsets, defined by PD-1 and TIM-3 expression, present varied cytokine responses in acute myeloid leukemia patients. Int Immunopharmacol 2020;80:106122. [PMID: 31955066 DOI: 10.1016/j.intimp.2019.106122] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
31 Chen L, Sun T, Kan X, Chen S, Ren Y, Cao Y, Yan L, Liang B, Xiong B, Zheng C. Transarterial chemoembolization combined with iodine-125 seed implantation for patients with hepatocellular carcinoma: a retrospective controlled study. J Int Med Res 2020;48:300060520944309. [PMID: 33050765 DOI: 10.1177/0300060520944309] [Reference Citation Analysis]
32 Chen M, Nie J, Liu Y, Li X, Zhang Y, Brock MV, Feng K, Wu Z, Li X, Shi L, Li S, Guo M, Mei Q, Han W. Phase Ib/II study of safety and efficacy of low-dose decitabine-primed chemoimmunotherapy in patients with drug-resistant relapsed/refractory alimentary tract cancer. Int J Cancer 2018;143:1530-40. [PMID: 29663379 DOI: 10.1002/ijc.31531] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
33 Chu H, Du F, Jiang L, Wang Z, Gong Z, Lian P, Li P, Chen J. The Efficacy of CIK-Based Immunotherapies for Advanced Solid Tumors. Technol Cancer Res Treat 2017;16:577-85. [PMID: 27436839 DOI: 10.1177/1533034616659163] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
34 Cui J, Li L, Wang C, Jin H, Yao C, Wang Y, Li D, Tian H, Niu C, Wang G. Combined cellular immunotherapy and chemotherapy improves clinical outcome in patients with gastric carcinoma. Cytotherapy. 2015;17:979-988. [PMID: 25890480 DOI: 10.1016/j.jcyt.2015.03.605] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
35 Zhou QH, Wu FT, Pang LT, Zhang TB, Chen Z. Role of γδT cells in liver diseases and its relationship with intestinal microbiota. World J Gastroenterol 2020; 26(20): 2559-2569 [PMID: 32523311 DOI: 10.3748/wjg.v26.i20.2559] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
36 Lee JH, Lee JH, Lim YS, Yeon JE, Song TJ, Yu SJ, Gwak GY, Kim KM, Kim YJ, Lee JW, Yoon JH. Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: an extended 5-year follow-up. Cancer Immunol Immunother. 2019;68:23-32. [PMID: 30232520 DOI: 10.1007/s00262-018-2247-4] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 8.0] [Reference Citation Analysis]
37 Niu C, Jin H, Li M, Xu J, Xu D, Hu J, He H, Li W, Cui J. In vitro analysis of the proliferative capacity and cytotoxic effects of ex vivo induced natural killer cells, cytokine-induced killer cells, and gamma-delta T cells. BMC Immunol 2015;16:61. [PMID: 26458364 DOI: 10.1186/s12865-015-0124-x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
38 Shan CC, Shi LR, Ding MQ, Zhu YB, Li XD, Xu B, Jiang JT, Wu CP. Cytokine-induced killer cells co-cultured with dendritic cells loaded with the protein lysate produced by radiofrequency ablation induce a specific antitumor response. Oncol Lett 2015;9:1549-56. [PMID: 25788999 DOI: 10.3892/ol.2015.2977] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
39 Rong X, Wei F, Li A, Xiao D, Luo R. Effective activity of cytokine induced killer cells against hepatocellular carcinoma including tumor-initiating cells. Med Hypotheses 2015;84:159-61. [PMID: 25636604 DOI: 10.1016/j.mehy.2014.08.022] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
40 da Costa AC, Sodergren M, Jayant K, Santa Cruz F, Spalding D, Pai M, Habib N. Radiofrequency combined with immunomodulation for hepatocellular carcinoma: State of the art and innovations. World J Gastroenterol 2020; 26(17): 2040-2048 [PMID: 32536773 DOI: 10.3748/wjg.v26.i17.2040] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
41 Ma Y, Wallace AN, Madaelil TP, Jennings JW. Treatment of osseous metastases using the Spinal Tumor Ablation with Radiofrequency (STAR) system. Expert Rev Med Devices 2016;13:1137-45. [PMID: 27807994 DOI: 10.1080/17434440.2016.1256772] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
42 Jin Y, Sun Z, Geng J, Yang L, Song Z, Song H, Wang J, Tang J. IL-21 reinvigorates exhausted natural killer cells in patients with HBV-associated hepatocellular carcinoma in STAT1-depedent pathway. Int Immunopharmacol 2019;70:1-8. [PMID: 30780004 DOI: 10.1016/j.intimp.2019.02.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
43 Li G, Staveley-O'Carroll KF, Kimchi ET. Potential of Radiofrequency Ablation in Combination with Immunotherapy in the Treatment of Hepatocellular Carcinoma. J Clin Trials. 2016;6. [PMID: 28042519 DOI: 10.4172/2167-0870.1000257] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
44 Qian L, Shen Y, Xie J, Meng Z. Immunomodulatory effects of ablation therapy on tumors: Potentials for combination with immunotherapy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2020;1874:188385. [DOI: 10.1016/j.bbcan.2020.188385] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
45 Giraudo L, Gammaitoni L, Cangemi M, Rotolo R, Aglietta M, Sangiolo D. Cytokine-induced killer cells as immunotherapy for solid tumors: current evidence and perspectives. Immunotherapy 2015;7:999-1010. [PMID: 26310715 DOI: 10.2217/imt.15.61] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
46 Tanoue S, Chang LY, Li Y, Kaplan DE. Monocyte-derived dendritic cells from cirrhotic patients retain similar capacity for maturation/activation and antigen presentation as those from healthy subjects. Cell Immunol 2015;295:36-45. [PMID: 25734547 DOI: 10.1016/j.cellimm.2015.02.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
47 Cai XR, Li X, Lin JX, Wang TT, Dong M, Chen ZH, Jia CC, Hong YF, Lin Q, Wu XY. Autologous transplantation of cytokine-induced killer cells as an adjuvant therapy for hepatocellular carcinoma in Asia: an update meta-analysis and systematic review. Oncotarget 2017;8:31318-28. [PMID: 28412743 DOI: 10.18632/oncotarget.15454] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
48 Qiu J, Lu W, Yu N, Yang G, Li Y, Huang Z, Li J, Li K, Xu H, Chen S, Zeng X, Liu H. HabibTM 4X-assisted resection versus clamp-crush resection for hepatocellular carcinoma: a propensity-matching study. Oncotarget 2017;8:4218-27. [PMID: 27965468 DOI: 10.18632/oncotarget.13906] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
49 Ding X, Cao H, Chen X, Jin H, Liu Z, Wang G, Cai L, Li D, Niu C, Tian H, Yang L, Zhao Y, Li W, Cui J. Cellular immunotherapy as maintenance therapy prolongs the survival of the patients with small cell lung cancer. J Transl Med 2015;13:158. [PMID: 25968637 DOI: 10.1186/s12967-015-0514-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
50 Chen CL, Pan QZ, Zhao JJ, Wang Y, Li YQ, Wang QJ, Pan K, Weng DS, Jiang SS, Tang Y, Zhang XF, Zhang HX, Zhou ZQ, Zeng YX, Xia JC. PD-L1 expression as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma. Oncoimmunology. 2016;5:e1176653. [PMID: 27622026 DOI: 10.1080/2162402x.2016.1176653] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 6.8] [Reference Citation Analysis]
51 Legut M, Cole DK, Sewell AK. The promise of γδ T cells and the γδ T cell receptor for cancer immunotherapy. Cell Mol Immunol 2015;12:656-68. [PMID: 25864915 DOI: 10.1038/cmi.2015.28] [Cited by in Crossref: 63] [Cited by in F6Publishing: 62] [Article Influence: 9.0] [Reference Citation Analysis]
52 Hoeres T, Smetak M, Pretscher D, Wilhelm M. Improving the Efficiency of Vγ9Vδ2 T-Cell Immunotherapy in Cancer. Front Immunol 2018;9:800. [PMID: 29725332 DOI: 10.3389/fimmu.2018.00800] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 13.5] [Reference Citation Analysis]
53 Saura-esteller J, de Jong M, King LA, Ensing E, Winograd B, de Gruijl TD, Parren PWHI, van der Vliet HJ. Gamma Delta T-Cell Based Cancer Immunotherapy: Past-Present-Future. Front Immunol 2022;13:915837. [DOI: 10.3389/fimmu.2022.915837] [Reference Citation Analysis]
54 Xie ZB, Zhu SL, Peng YC, Chen J, Wang XB, Ma L, Bai T, Xiang BD, Li LQ, Zhong JH. Postoperative hepatitis B virus reactivation and surgery-induced immunosuppression in patients with hepatitis B-related hepatocellular carcinoma. J Surg Oncol 2015;112:634-42. [PMID: 26421419 DOI: 10.1002/jso.24044] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
55 Künkele KP, Wesch D, Oberg HH, Aichinger M, Supper V, Baumann C. Vγ9Vδ2 T Cells: Can We Re-Purpose a Potent Anti-Infection Mechanism for Cancer Therapy? Cells 2020;9:E829. [PMID: 32235616 DOI: 10.3390/cells9040829] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
56 Pan QZ, Tang Y, Wang QJ, Li YQ, Zhang L, Li XD, Zhao JJ, Weng DS, Liu Q, Huang LX, He J, Chen SP, Ke ML, Zeng YX, Xia JC. Adjuvant cellular immunotherapy in patients with resected primary non-small cell lung cancer. Oncoimmunology 2015;4:e1038017. [PMID: 26405607 DOI: 10.1080/2162402X.2015.1038017] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
57 Tsuchiya N, Sawada Y, Endo I, Uemura Y, Nakatsura T. Potentiality of immunotherapy against hepatocellular carcinoma. World J Gastroenterol 2015; 21(36): 10314-10326 [PMID: 26420958 DOI: 10.3748/wjg.v21.i36.10314] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
58 Qian L, Wang N, Tian H, Jin H, Zhao H, Niu C, He H, Ge T, Han W, Hu J, Li D, Han F, Xu J, Ding X, Chen J, Li W, Cui J. Corrigendum to “Dual Effects of Cellular Immunotherapy in Inhibition of Virus Replication and Prolongation of Survival in HCV-Positive Hepatocellular Carcinoma Patients”. Journal of Immunology Research 2022;2022:1-2. [DOI: 10.1155/2022/9761463] [Reference Citation Analysis]
59 Ma W, Chen X, Yuan Y. T-cell-associated immunotherapy: a promising strategy for the treatment of hepatocellular carcinoma. Immunotherapy 2017;9:523-5. [PMID: 28595519 DOI: 10.2217/imt-2017-0053] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
60 Wang P, Tian M, Ren W. Correlation Between Contrast-Enhanced Ultrasound and Immune Response of Distant Hepatocellular Carcinoma After Radiofrequency Ablation in a Murine Model. J Ultrasound Med 2021. [PMID: 34018628 DOI: 10.1002/jum.15753] [Reference Citation Analysis]
61 Sparchez Z, Radu P, Bartos A, Nenu I, Craciun R, Mocan T, Horhat A, Spârchez M, Dufour JF. Combined treatments in hepatocellular carcinoma: Time to put them in the guidelines? World J Gastrointest Oncol 2021; 13(12): 1896-1918 [DOI: 10.4251/wjgo.v13.i12.1896] [Reference Citation Analysis]
62 Liu Z, Liu X, Liang J, Liu Y, Hou X, Zhang M, Li Y, Jiang X. Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects. Front Immunol 2021;12:765101. [PMID: 34675942 DOI: 10.3389/fimmu.2021.765101] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Dumolard L, Ghelfi J, Roth G, Decaens T, Macek Jilkova Z. Percutaneous Ablation-Induced Immunomodulation in Hepatocellular Carcinoma. Int J Mol Sci. 2020;21. [PMID: 32575734 DOI: 10.3390/ijms21124398] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
64 Huang J, Kan Q, Lan, Zhao X, Zhang Z, Yang S, Li H, Wang L, Xu L, Cheng Z, Zhang Y. Chemotherapy in combination with cytokine-induced killer cell transfusion: An effective therapeutic option for patients with extensive stage small cell lung cancer. International Immunopharmacology 2017;46:170-7. [DOI: 10.1016/j.intimp.2016.12.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
65 Canale M, Ulivi P, Foschi FG, Scarpi E, De Matteis S, Donati G, Ercolani G, Scartozzi M, Faloppi L, Passardi A, Tamburini E, Valgiusti M, Marisi G, Frassineti GL, Casadei Gardini A. Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma. Critical Reviews in Oncology/Hematology 2018;129:44-53. [DOI: 10.1016/j.critrevonc.2018.06.017] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]